Testing effectiveness (Phase 2)Study completedNCT03845296
What this trial is testing
Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
Who this might be right for
Deleterious BRCA1 Gene MutationDeleterious BRCA2 Gene MutationLoss of Heterozygosity+8 more
SWOG Cancer Research Network 64